TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance

Core Viewpoint - TriSalus Life Sciences, Inc. reported strong commercial performance in Q3 2025, highlighting its innovative approach in oncology and the integration of novel delivery technology with standard therapies [1] Financial Results - The company announced its financial results for the quarter ended September 30, 2025, indicating a positive trend in revenue generation and operational efficiency [1] Operational Update - TriSalus provided an operational update, emphasizing its investigational immunotherapeutic aimed at transforming treatment for patients with solid tumors, which reflects the company's commitment to advancing cancer care [1]